Daniel Nadeau, MD
Endocrinology, Diabetes & Metabolism · Newport Beach, CANPI 1215902226
Payments from drug & device makers
Across 2,111 payments — averaging $550.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$659K
- Novo Nordisk$325K
- Boehringer Ingelheim$95K
- AstraZeneca$40K
- Dexcom, Inc.$15K
- Bayer$10K
- plus $19K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1,015 | $658,564 |
| Novo Nordisk | 490 | $324,569 |
| Boehringer Ingelheim | 166 | $94,891 |
| AstraZeneca(2 entities) | 92 | $40,449 |
| Dexcom, Inc. | 75 | $15,409 |
| Bayer | 37 | $9,907 |
| Cequr Corporation | 6 | $8,873 |
| Insulet Corporation | 15 | $3,732 |
| Mannkind Corporation | 53 | $1,322 |
| Amgen(2 entities) | 24 | $1,015 |
| Radius Health, Inc. | 25 | $517 |
| Corcept Therapeutics | 9 | $439 |
| Tandem Diabetes Care, Inc. | 15 | $401 |
| Abbott | 10 | $366 |
| Sanofi-aventis U.S. LLC | 10 | $308 |
| Sequel Med Tech, LLC | 5 | $281 |
| AbbVie | 18 | $264 |
| Medtronic | 4 | $240 |
| Johnson & Johnson | 3 | $155 |
| Kyowa Kirin, Inc. | 4 | $120 |
| Lexicon Pharmaceuticals, Inc. | 1 | $119 |
| Intra-sana Laboratories | 3 | $119 |
| Regeneron Healthcare Solutions, Inc. | 1 | $117 |
| Alvogen Inc | 5 | $98 |
| IBSA Pharma Inc. | 5 | $90 |
| Amarin Pharma, Inc. | 5 | $87 |
| BETA Bionics, Inc. | 2 | $63 |
| Novartis | 4 | $59 |
| Antares Pharma, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Lifescan, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
How this compares
$1,162,739 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Newport Beach
- David AhnNewport Beach$5.8M
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.